Boundless Bio, Inc. BOLD
2.46 USD +0.01 (+0.41%)
At closeNov 11, 2026, 4:00 PM EST
2.46 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
2.39 Day range 2.46
0.961 52-week range 3.16
- YTD
- +105.00%
- 1 year
- +95.24%
News
benzinga.com Callio Therapeutics Appoints Zachary Hornby As CEO Veteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancerPiers Ingram, PhD, Co-Founder, transitions to…- benzinga.com Boundless Bio Q2 EPS $(1.06) Misses $(0.61) Estimate Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.61) by 73.77 percent. This is a 51.43 percent decrease over losses of…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular session. Atlantic International (NASDAQ:ATLN) stock rose 143.31% to $1.07. The market value of their…
benzinga.com Crude Oil Down Over 1%; US Manufacturing PMI Surges In June US stocks lower, Nasdaq falls 500 points. Dow down 0.04%, Nasdaq 1.91%, S&P 500 1.27%. Consumer staples up 1.4%, tech down 2.3%. S&P PMI rises.
benzinga.com Dow Falls Over 300 Points; Korn Ferry Earnings Top Views US stocks down as Dow falls 300 points, while S&P 500 and NASDAQ also decrease. Consumer staples rise, tech stocks fall. Korn Ferry beats earnings.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers HeartSciences (NASDAQ:HSCS) stock rose 82.2% to $3.23 during Tuesday's pre-market session. The company's market cap stands at $5.6 million. Boundless Bio (NASDAQ:BOLD) shares rose 62.85% to…
benzinga.com Boundless Bio, Serapha Bio Ink All-Stock Merger Agreement; Combined Entity Anticipated To Trade On Nasdaq Under AATD Symbol Boundless Bio, Inc. (Nasdaq: BOLD) and Serapha Bio, Inc., a privately held biotechnology company developing an investigational in vivo base editing therapy for Alpha-1 Antitrypsin Deficiency (AATD),…
benzinga.com Boundless Bio Q1 EPS $(0.60) Beats $(0.64) Estimate Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.64) by 4.76 percent. This is a 15.49 percent increase over losses of…
benzinga.com Boundless Bio Reveals Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Boundless Bio To Present Oral Kinesin Degrader Program At The AACR Annual Meeting 2026 Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene…
benzinga.com Boundless Bio Q4 EPS $(0.58) Misses $(0.52) Estimate Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.52) by 11.54 percent. This is a 21.62 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com The FDA Accepts Boundless Bio's Investigational New Drug Application for BBI-940; Also, the Company Will Cease Enrollment in Phase 1/2 POTENTIATE Trial of BBI-355 Combined With BBI-825 in Oncogene-amplified Cancers BBI-940 novel Kinesin degrader programThe acceptance of the BBI-940 IND enables Boundless to advance the program into a first-in-human clinical trial for patients with metastatic breast cancer,…
- benzinga.com Boundless Bio Q3 EPS $(0.62) Misses $(0.53) Estimate Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.53) by 16.32 percent. This is a 16.22 percent increase over losses of…
benzinga.com Stocks That Hit 52-Week Highs On Friday - benzinga.com The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday
- benzinga.com Benzinga's Top Upgrades, Downgrades For October 3, 2019
benzinga.com 75 Biggest Movers From Yesterday - benzinga.com Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 7, 2018
- benzinga.com 88 Biggest Movers From Yesterday
- benzinga.com 70 Stocks Moving In Wednesday's Mid-Day Session